Teosyal RHA KISS with Lidocaine (2 x 0.7 ml)

Teosyal

Dermal filler

Hyaluronic acid lip filler for dynamic lip reshaping and perioral wrinkles

CE Marked Class III medical device in the European Union/EEA and other CE Recognising markets, for injection in the perioral region including lips and oral commissures.
Manufactured by Teoxane SA under ISO 13485 Compliant quality management systems for medical devices.
Uses non Animal Origin hyaluronic acid with very low residual BDDE levels (<1 ppm) and defined crosslinking degree (<5%), in line with international safety and quality requirements for injectable HA fillers.

CE Marked Class III medical device in the European Union/EEA and other CE Recognising markets, for injection in the perioral region including lips and oral commissures.
Manufactured by Teoxane SA under ISO 13485 Compliant quality management systems for medical devices.
Uses non Animal Origin hyaluronic acid with very low residual BDDE levels (<1 ppm) and defined crosslinking degree (<5%), in line with international safety and quality requirements for injectable HA fillers.
Supplied with eIFU and Summary of Safety and Clinical Performance (SSCP) referenced in accordance with EU MDR requirements.

Description

Teosyal RHA KISS with Lidocaine (2 x 0.7 ml) is a sterile, transparent, non-pyrogenic, viscoelastic gel of cross-linked, non-animal hyaluronic acid specifically designed for subtle lip reshaping and treatment of the perioral region. Part of Teoxane’s multi-award-winning RHA (Resilient Hyaluronic Acid) collection, RHA KISS is engineered to adapt to dynamic movements of the mouth while maintaining natural expression, volume and hydration. Each 0.7 ml prefilled syringe contains 23 mg/ml hyaluronic acid, cross-linked with BDDE, and 0.3% lidocaine hydrochloride to improve injection comfort. The filler creates volume to enhance and contour the lips, corrects asymmetries, and smooths fine lines and wrinkles around the mouth, including perioral rhytids and oral commissures. As a biodegradable implant, Teosyal RHA KISS is progressively resorbed over time, with an estimated lifetime of approximately 12–18 months when used according to the Instructions for Use. It is CE-marked as a Class III medical device and intended exclusively for use by trained healthcare professionals.

Bnefits

Specifically developed for dynamic, subtle lip reshaping and contouring, providing natural-looking volume and definition.
Enhances lip volume for naturally fuller lips while respecting lip mobility and expression.
Targets the perioral region, helping to smooth fine lines and wrinkles in and around the lips, including perioral lines and oral commissures.
Delivers deep, long-lasting hydration to injected areas due to the high concentration of hyaluronic acid (23 mg/ml).
Resilient Hyaluronic Acid (RHA) technology allows the gel to adapt to facial movement, preserving skin vitality and softness.
Contains 0.3% lidocaine hydrochloride to reduce injection discomfort and improve patient experience during treatment.
Biodegradable and resorbable hyaluronic acid implant with an estimated durability of 12–18 months, depending on patient and treatment factors.
Supplied as ready-to-use prefilled syringes with appropriate fine needles (30G 1/2") and traceability labels, supporting safe and standardised clinical use.
Non-animal-origin, highly purified hyaluronic acid gel with very low residual BDDE (<1 ppm) and degree of crosslinking <5%.
Part of Teoxane’s CE-marked Teosyal RHA range, manufactured under stringent Swiss quality and ISO 13485 medical device standards.

Lpgclinicswholesale

Teosyal RHA 3 Lidocaine (2 x 1ml)

Aesthetic Injectables

£98.99
£119.00
0 more

Dermafillerltd

Teosyal RHA 4 Lidocaine (2 x 1.0 ml)

Aesthetic Injectables

£130.00
£130.00
0 more

$TEOSYAL\u00ae PureSense Deep Lines (2 x 1 ml)$

Multiple distributors

TEOSYAL® PureSense Deep Lines (2 x 1 ml)

Aesthetic Injectables

£109.99
£120.00
1 more

Usage

For professional use only: TEOSYAL RHA KISS must be administered exclusively by well-trained, qualified healthcare professionals who are authorised under local regulations and experienced in hyaluronic acid filler injection and facial anatomy.
Before treatment, obtain a complete medical history including allergies (especially to hyaluronic acid, lidocaine or other amide-type local anaesthetics), autoimmune diseases, cardiac or hepatic disorders, epilepsy, porphyria, bleeding disorders, medications (e.g. anticoagulants, beta blockers), previous aesthetic treatments and history of severe allergy/anaphylaxis.
Assess the perioral region and lips, define realistic treatment goals with the patient, explain expected outcomes, potential side effects, contraindications and precautions, and obtain informed consent.
Inspect packaging before use: do not use if blister or syringe is damaged, opened prematurely, past expiry date, or if the gel appears cloudy, separated, contains bubbles or particulates.
Store and handle under aseptic conditions. Disinfect the treatment area thoroughly with an appropriate antiseptic solution and use sterile gloves and equipment.
Mount a supplied sterile 30G 1/2" needle (or an appropriate alternative sterile needle or verified compatible cannula, e.g. 25G) securely onto the luer-lock syringe following the instructions. Do not over-tighten or apply lateral force.
Expel any air bubbles and prime the needle by gently depressing the plunger until a small droplet appears at the tip.
Depending on the area to be treated, inject slowly at variable depths: into the dermis, subcutaneously, into the subdermis, or into the submucosa of the red lips, as guided by the Instructions for Use and clinical judgement.
Use appropriate injection techniques (e.g. serial puncture, linear threading, fanning, small bolus injections) according to the indication, anatomy and desired result. The healthcare professional selects the technique and volume based on individual needs.
Avoid injecting into or close to blood vessels or nerves. Inject slowly with minimal pressure and, where clinically appropriate, aspirate according to local practice to help reduce the risk of intravascular injection.
Do not inject into the most superficial layer of the skin (epidermis) or at depths other than those recommended in the IFU, and do not mix in the same syringe with other products.
Do not exceed a total of 6 ml per treatment session across all sites; for lip indications specifically, a maximum of 2 ml per session is recommended.
After injection, stop injecting before withdrawing the needle or cannula to avoid product reflux, then gently massage the treated areas to ensure uniform distribution, avoiding excessive pressure.
At the end of the session, discard any remaining unused product; the syringe and needles are single-use only and must not be re-sterilised or reused. Dispose of them in approved sharps containers.
Prior to treatment, advise patients to avoid high doses of vitamin E, aspirin, NSAIDs or anticoagulants in the week before injection where medically appropriate, to reduce the risk of bruising (in accordance with their prescribing physician’s advice).
Post-treatment, instruct patients not to wear make-up on treated areas for approximately 12 hours and to avoid dental treatments, other aesthetic procedures, extended sun or UV exposure, and extreme temperatures (intense cold, sauna, hammam, etc.) for about two weeks after injection.
Warn patients about signs of vascular compromise (skin whitening or marbling, severe pain, numbness) and instruct them to seek immediate medical attention if such symptoms occur. If any sign appears during injection, stop injection and implement appropriate management protocols.
Provide the patient with an implant card and retain traceability labels in the medical record. Inform them of the device details and how to report any adverse events.

Consentz Hub

Teosyal RHA KISS with Lidocaine (2 x 0.7 ml)

Description